Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances? Biopreservation and cell processing are critical pain points in scaling advanced therapies for global distribution, with variables like cryoprotectant toxicity, transport stability, and automation dictating both cost and clinical success.
Sean Werner, CTO of Cell Processing at BioLife Solutions and former Sexton Biotechnologies leader, has seen the real cost when assumptions break down at scale. From container fractures to uncertain analytics, he’s guided teams through the frontline challenges of CMC and biologics.
Topics discussed:
Why decentralized manufacturing and local storage might be the most practical path forward for delivering cell therapies globally (03:05)
Key distribution chain challenges—how logistics complexity escalates with cross-border shipments and the risks of primary packaging failure (03:44)
Regulatory expectations for transport validation and the importance of container integrity during shipping (04:49)
The growing role of automation and closed systems in reducing manual steps, with a look at current capabilities and future directions (06:41)
How more advanced analytics could unlock greater efficiencies and reduce manufacturing costs in cell therapy (07:49)
Practical guidance for scientists looking to optimize freezing and thawing processes, including common assumptions to avoid (08:39)
When it makes sense to use DMSO, risk management considerations, and whether DMSO-free really means safer (10:39)
Long-term aspirations for room-temperature biopreservation and challenging industry assumptions about stability (13:13)
The importance of process control and attention to detail in minimizing variability and improving clinical outcomes (14:44)
Smart insight: Sean Werner challenged the field to move beyond the cryo status quo: can we develop technologies for stable room temperature storage of living cells and biologics? While the hurdles are immense, questioning established dogma is the only route to transformative change. Above all, he warned, never treat biopreservation as an afterthought—the variability it introduces can undermine even the most promising therapies . As cell therapy matures, early and continual investment in process innovation and discipline will remain key.
If this episode has you rethinking freeze-thaw, here’s where to go next. Start with the science behind cryopreservation, then compare two takes on cryoprotectants: DMSO-free formulations and antifreeze-inspired chemistry.
Episodes 241 - 242: DMSO in Cell Therapy: Why Viability Scores Hide the Real Toxicity with Steve Oh
Episodes 161 - 162: How to Achieve 85%+ Cell Recovery Without DMSO’s Toxic Side Effects with Jeffrey Allen
Episodes 65 - 66: Freezing and Thawing Cells: the Science Behind Cryopreservation with Mark Davison
Episodes 129 - 130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster
Connect with Sean Werner:
 Website: www.biolifesolutions.com
LinkedIn: https://www.linkedin.com/in/sean-werner-54688326/
Support the show

The integrity of individual cells is the cornerstone of breakthrough cell and gene therapies—but translating lab discoveries into clinical success demands mastering cryopreservation challenges rarely discussed in depth.
Sean Werner, Chief Technology Officer of Cell Processing at BioLife Solutions,a leading provider of bioproduction tools and services to the cell and gene therapy and broader biopharma markets, has dedicated his career to safeguarding cell viability from the lab bench through to clinical application.
Topics discussed:
Sean Werner's unconventional career progression and early experiences in regenerative medicine (03:22)
The critical role of cryopreservation in cell and gene therapy product quality (05:59)
Biophysics of freezing: ice nucleation, supercooling, and their impact on cell viability (07:32)
Hidden pitfalls in cryopreservation, including ice recrystallization and osmotic stress (07:43)
Real-world challenges during clinical handling and thawing of cell therapies (11:18)
Why the commonly used -1°C per minute freeze rate is not universally optimal (13:09)
Difficulties in tracing clinical problems back to early cryopreservation choices (13:54)
Importance of evaluating long-term cell function, not just post-thaw viability (15:08)
Regulatory expectations around freeze-thaw processes in therapy manufacturing (16:34)
Smart insight: Success in cell therapy and advanced biologics is inseparable from mastery of cryopreservation. By adopting an experimental and data-driven mindset—questioning assumptions, customizing protocols, and measuring what truly matters—scientists can better fulfill that original promise: that a single cell, carefully protected, can change the course of medicine for patients worldwide.
If this episode has you rethinking freeze-thaw, here’s where to go next. Start with the science behind cryopreservation, then compare two takes on cryoprotectants: DMSO-free formulations and antifreeze-inspired chemistry.
Episodes 241 - 242: DMSO in Cell Therapy: Why Viability Scores Hide the Real Toxicity with Steve Oh
Episodes 161 - 162: How to Achieve 85%+ Cell Recovery Without DMSO’s Toxic Side Effects with Jeffrey Allen
Episodes 65 - 66: Freezing and Thawing Cells: the Science Behind Cryopreservation with Mark Davison
Episodes 129 - 130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster
Connect with Sean Werner:
 Website: www.biolifesolutions.com
LinkedIn: https://www.linkedin.com/in/sean-werner-54688326/
Support the show

Biologics development is full of hidden pitfalls, from selecting the right cell line to navigating analytical assessments that can make or break a therapy's success.
Today, we feature Lars Stöckl and Lena Tholen, industry experts from FyoniBio GmbH, who have deep experience guiding biotech teams through the maze of CMC development, troubleshooting both common and unusual product quality challenges.
Topics discussed:
Key factors in selecting host cell lines and the importance of matching the platform to molecule complexity (02:34)
The role of broad analytical assays early in cell line and pool development for better decision-making (03:34)
Glycosylation, post-translational modifications, and analytical strategies for both standard antibodies and more complex biotherapeutics (05:10)
When and how to conduct developability and manufacturability assessments, especially for novel or specialized molecules (06:55)
Troubleshooting glycosylation and aggregation problems—when to tweak the process and when to reconsider the molecule (08:05)
Importance of clear, direct communication with clients regarding manufacturability and process viability (09:32)
Example of how different CHO cell lines can dramatically impact molecule outcome and company trajectory (12:08)
Keeping pace with technological advances through collaboration, conferences, and feasibility studies with startups (13:55)
The move toward customization over standardization in cell line and process development (18:07)
Smart insight: The future of bioprocess development lies in a customized, molecule-centric approach. Rather than relying on generic, pre-set development platforms, success comes from carefully matching cell lines, processes, and analytical methods to the unique requirements of each molecule. True innovation and commercial success arise from adapting everything—cell line, process, analytics—to the molecule at hand.
Lars and Lena’s main point is that early choices about the host cell line, the analytics and the partner decide what’s possible later on. The episodes below take that idea further. One looks at the mechanics of cell line development, one at why promising molecules fail to manufacture, and two at outsourcing CMC work from the sponsor’s side.
Episodes 117 - 118: Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough
Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
Episodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist’s Guide to CDMO Selection with Sigma Mostafa
Episodes 71 - 72: Effective Outsourcing: How Small Biotech Companies Can Thrive with Mark Melville
Connect with Lars Stöckl and Lena Tholen:
 Website: www.fyonibio.com
LinkedIn:www.linkedin.com/in/dr-lars-stoeckl
LinkedIn: www.linkedin.com/in/lena-tholen-80642a11a
Support the show

How can small biotech companies navigate increasing molecular complexity, tight budgets, and the ever-present pressure to accelerate timelines while ensuring long-term process success?
In this episode, David Brühlmann welcomes Lena Tholen and Lars Stöckl of FyoniBio GmbH—two scientists who’ve dedicated their careers to optimizing cell line and process development for biopharma clients.
Topics covered in this episode:
The trend toward outsourcing CMC development and the reasons behind it for both large pharma and small biotechs (07:27)
How specialized CDMOs innovate and continuously improve cell line development platforms, giving clients access to new options and efficiencies (10:36)
Real-world experience navigating project pitfalls from discovery to clinical studies—including differences between cell lines and processes (13:38)
The importance of retaining key activity assays and critical knowledge in-house—and the risks of over-reliance on consultants (15:04)
Key factors that help biotech companies thrive when partnering with CDMOs, including internal expertise, flexibility, and milestone planning (17:32)
Smart insight: Product quality and success are designed in early through careful choices about cell lines, processes, and analytical strategies. Streamlined outsourcing and platform innovation can turbocharge development, but only when matched with committed, knowledgeable in-house leadership and measured, forward-thinking investment. The next time a CMC decision seems minor or a shortcut tempting, remember the long game—your product quality, speed to clinic, and future cost may all depend on it.
Lars and Lena’s main point is that early choices about the host cell line, the analytics and the partner decide what’s possible later on. The episodes below take that idea further. One looks at the mechanics of cell line development, one at why promising molecules fail to manufacture, and two at outsourcing CMC work from the sponsor’s side.
Episodes 117 - 118: Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough
Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
Episodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist’s Guide to CDMO Selection with Sigma Mostafa
Episodes 71 - 72: Effective Outsourcing: How Small Biotech Companies Can Thrive with Mark Melville
Connect with Lars Stöckl and Lena Tholen:
 Website: www.fyonibio.com
LinkedIn:www.linkedin.com/in/dr-lars-stoeckl
LinkedIn: www.linkedin.com/in/lena-tholen-80642a11a
Support the show

Is your process model gathering dust while real-world decisions march on without it? Many technically strong digital tools—no matter how powerful—end up sidelined in bioprocess development. Why is that, and what does it actually take for digital modeling to earn its place at the lab bench?
In this episode, David Brühlmann sits down with Moritz von Stosch of HINA Bioventures, a scientist-turned-investor who’s navigated both the technology provider and pharma end-user sides. Moritz von Stosch brings firsthand insights from building digital solutions, deploying them in pharma, and evaluating what actually sticks when the clock is ticking and the stakes are high.
Topics discussed:
The importance of starting with your purpose when selecting a modeling strategy (03:00)
Experimental design: when to use factorial versus random space-filling designs, and the inherent biases each can introduce (04:22)
The future of agentic workflows, AI, and autonomous labs in bioprocessing, including the importance and challenges of sensor technologies (06:02)
Practical hurdles to implementing fully autonomous laboratories, and the non-obvious value humans still bring (09:09)
Adapting mindsets for the evolving role of the bioprocess engineer in a more automated, agent-driven workflow (11:48)
Advice for biotech professionals on how to assess the real value in new technologies versus hype, and the role of proprietary algorithms and company stability (13:33)
How cultural factors, not just technology, shape the adoption of modeling and digital tools in biotech (16:02)
Strategies to help the bioprocess community adopt more innovation while ensuring compliance in regulated environments (17:14)
Three key takeaways for staying relevant—including generating data for tomorrow’s questions and balancing curiosity, experimentation, and oversight (19:14)
Smart insight: Three takeaways from Moritz von Stosch:
Generate data for tomorrow’s questions, not just today’s.
Be curious—try, adapt, don’t over-plan.
Stay relevant: Use digital tools but keep your human edge (creativity, critical thinking).
To keep exploring how modeling and prior knowledge can speed up process development, check out these related conversations:
Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov
Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey
Episodes 277 - 278: Your Bioprocess Data Already Holds 35% More Yield: From End-to-End Models to Digital Twins with Ignasi Bofarull-Manzano
Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya Burkov
Connect with Moritz von Stosch:
 Website: www.hinabioventures.com
LinkedIn: www.linkedin.com/in/movosto
Support the show